Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SOD1 | P00441 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7970502 | 0.82 | QPCT (0.63) | QPCTSOD1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3872082 | 0.81 | QPCT (0.62) | QPCTSOD1ALDH1A1L3MBTL1 | |
| SCHEMBL9940645 | 0.80 | MAPT (0.54) | QPCTKMT2AMAPTLMNACYP1A2 | |
| SCHEMBL15586066 | 0.76 | HTT (0.42) | QPCTKMT2AMAPTLMNAMEN1 | |
| SCHEMBL10653756 | 0.75 | MAPT (0.66) | KMT2AMAPTLMNACYP1A2CYP3A4 | |
| SCHEMBL2539814 | 0.74 | SOD1 (0.57) | QPCTKMT2AMEN1SOD1 | |
| SCHEMBL4939445 | 0.74 | QPCT (0.52) | QPCTMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL291484 | 0.73 | QPCT (0.54) | QPCTKMT2ALMNAMEN1SOD1 | |
| SCHEMBL8444354 | 0.73 | LMNA (0.58) | QPCTKMT2AMAPTLMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL6383071 | 0.72 | QPCT (0.50) | QPCTKMT2AMAPTLMNASOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| EP-2651903-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | Janssen R&D Ireland (IE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080446-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080446-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | SBDS, CHUK, HAT1 | QPCT 3280/4885KMT2A 890/4885MAPT 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.